JP2006508096A - 没食子酸エピガロカテキンを含む新規な栄養補助組成物 - Google Patents
没食子酸エピガロカテキンを含む新規な栄養補助組成物 Download PDFInfo
- Publication number
- JP2006508096A JP2006508096A JP2004548728A JP2004548728A JP2006508096A JP 2006508096 A JP2006508096 A JP 2006508096A JP 2004548728 A JP2004548728 A JP 2004548728A JP 2004548728 A JP2004548728 A JP 2004548728A JP 2006508096 A JP2006508096 A JP 2006508096A
- Authority
- JP
- Japan
- Prior art keywords
- egcg
- composition
- pantethine
- body weight
- acid
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
- 239000000203 mixture Substances 0.000 title claims abstract description 73
- WMBWREPUVVBILR-WIYYLYMNSA-N (-)-Epigallocatechin-3-o-gallate Chemical compound O([C@@H]1CC2=C(O)C=C(C=C2O[C@@H]1C=1C=C(O)C(O)=C(O)C=1)O)C(=O)C1=CC(O)=C(O)C(O)=C1 WMBWREPUVVBILR-WIYYLYMNSA-N 0.000 title claims abstract description 58
- WMBWREPUVVBILR-UHFFFAOYSA-N GCG Natural products C=1C(O)=C(O)C(O)=CC=1C1OC2=CC(O)=CC(O)=C2CC1OC(=O)C1=CC(O)=C(O)C(O)=C1 WMBWREPUVVBILR-UHFFFAOYSA-N 0.000 title claims abstract description 58
- 235000015872 dietary supplement Nutrition 0.000 title claims abstract description 22
- 229940030275 epigallocatechin gallate Drugs 0.000 title description 45
- RLCKHJSFHOZMDR-UHFFFAOYSA-N (3R, 7R, 11R)-1-Phytanoid acid Natural products CC(C)CCCC(C)CCCC(C)CCCC(C)CC(O)=O RLCKHJSFHOZMDR-UHFFFAOYSA-N 0.000 claims abstract description 55
- RLCKHJSFHOZMDR-PWCSWUJKSA-N 3,7R,11R,15-tetramethyl-hexadecanoic acid Chemical compound CC(C)CCC[C@@H](C)CCC[C@@H](C)CCCC(C)CC(O)=O RLCKHJSFHOZMDR-PWCSWUJKSA-N 0.000 claims abstract description 53
- DJWYOLJPSHDSAL-ROUUACIJSA-N pantethine Chemical compound OCC(C)(C)[C@@H](O)C(=O)NCCC(=O)NCCSSCCNC(=O)CCNC(=O)[C@H](O)C(C)(C)CO DJWYOLJPSHDSAL-ROUUACIJSA-N 0.000 claims abstract description 49
- DJWYOLJPSHDSAL-UHFFFAOYSA-N Pantethine Natural products OCC(C)(C)C(O)C(=O)NCCC(=O)NCCSSCCNC(=O)CCNC(=O)C(O)C(C)(C)CO DJWYOLJPSHDSAL-UHFFFAOYSA-N 0.000 claims abstract description 48
- 229960000903 pantethine Drugs 0.000 claims abstract description 48
- 235000008975 pantethine Nutrition 0.000 claims abstract description 48
- 239000011581 pantethine Substances 0.000 claims abstract description 48
- ACTIUHUUMQJHFO-UPTCCGCDSA-N coenzyme Q10 Chemical compound COC1=C(OC)C(=O)C(C\C=C(/C)CC\C=C(/C)CC\C=C(/C)CC\C=C(/C)CC\C=C(/C)CC\C=C(/C)CC\C=C(/C)CC\C=C(/C)CC\C=C(/C)CCC=C(C)C)=C(C)C1=O ACTIUHUUMQJHFO-UPTCCGCDSA-N 0.000 claims abstract description 44
- AGBQKNBQESQNJD-UHFFFAOYSA-M lipoate Chemical compound [O-]C(=O)CCCCC1CCSS1 AGBQKNBQESQNJD-UHFFFAOYSA-M 0.000 claims abstract description 40
- 235000019136 lipoic acid Nutrition 0.000 claims abstract description 40
- 229960002663 thioctic acid Drugs 0.000 claims abstract description 40
- 229960001109 policosanol Drugs 0.000 claims abstract description 28
- BDERNNFJNOPAEC-UHFFFAOYSA-N propan-1-ol Chemical compound CCCO BDERNNFJNOPAEC-UHFFFAOYSA-N 0.000 claims abstract description 28
- 238000011282 treatment Methods 0.000 claims abstract description 22
- 239000002207 metabolite Substances 0.000 claims abstract description 12
- 230000002265 prevention Effects 0.000 claims abstract description 10
- 208000008589 Obesity Diseases 0.000 claims abstract description 9
- 235000020824 obesity Nutrition 0.000 claims abstract description 9
- 230000037396 body weight Effects 0.000 claims description 28
- 208000001072 type 2 diabetes mellitus Diseases 0.000 claims description 28
- 235000013305 food Nutrition 0.000 claims description 22
- 208000002705 Glucose Intolerance Diseases 0.000 claims description 16
- 235000013361 beverage Nutrition 0.000 claims description 16
- 201000009104 prediabetes syndrome Diseases 0.000 claims description 16
- 206010067584 Type 1 diabetes mellitus Diseases 0.000 claims description 13
- 238000000034 method Methods 0.000 claims description 11
- 206010018429 Glucose tolerance impaired Diseases 0.000 claims description 10
- 239000008194 pharmaceutical composition Substances 0.000 claims description 9
- 239000002417 nutraceutical Substances 0.000 claims description 8
- 235000021436 nutraceutical agent Nutrition 0.000 claims description 8
- 239000013589 supplement Substances 0.000 claims description 4
- 239000007787 solid Substances 0.000 claims description 3
- 239000002253 acid Substances 0.000 claims description 2
- 238000004519 manufacturing process Methods 0.000 claims description 2
- 102100022043 Coenzyme Q-binding protein COQ10 homolog A, mitochondrial Human genes 0.000 claims 2
- 101710154595 Coenzyme Q-binding protein COQ10 homolog A, mitochondrial Proteins 0.000 claims 2
- 208000024891 symptom Diseases 0.000 claims 1
- 206010012601 diabetes mellitus Diseases 0.000 abstract description 21
- 239000004615 ingredient Substances 0.000 description 30
- 239000004480 active ingredient Substances 0.000 description 24
- NOESYZHRGYRDHS-UHFFFAOYSA-N insulin Chemical compound N1C(=O)C(NC(=O)C(CCC(N)=O)NC(=O)C(CCC(O)=O)NC(=O)C(C(C)C)NC(=O)C(NC(=O)CN)C(C)CC)CSSCC(C(NC(CO)C(=O)NC(CC(C)C)C(=O)NC(CC=2C=CC(O)=CC=2)C(=O)NC(CCC(N)=O)C(=O)NC(CC(C)C)C(=O)NC(CCC(O)=O)C(=O)NC(CC(N)=O)C(=O)NC(CC=2C=CC(O)=CC=2)C(=O)NC(CSSCC(NC(=O)C(C(C)C)NC(=O)C(CC(C)C)NC(=O)C(CC=2C=CC(O)=CC=2)NC(=O)C(CC(C)C)NC(=O)C(C)NC(=O)C(CCC(O)=O)NC(=O)C(C(C)C)NC(=O)C(CC(C)C)NC(=O)C(CC=2NC=NC=2)NC(=O)C(CO)NC(=O)CNC2=O)C(=O)NCC(=O)NC(CCC(O)=O)C(=O)NC(CCCNC(N)=N)C(=O)NCC(=O)NC(CC=3C=CC=CC=3)C(=O)NC(CC=3C=CC=CC=3)C(=O)NC(CC=3C=CC(O)=CC=3)C(=O)NC(C(C)O)C(=O)N3C(CCC3)C(=O)NC(CCCCN)C(=O)NC(C)C(O)=O)C(=O)NC(CC(N)=O)C(O)=O)=O)NC(=O)C(C(C)CC)NC(=O)C(CO)NC(=O)C(C(C)O)NC(=O)C1CSSCC2NC(=O)C(CC(C)C)NC(=O)C(NC(=O)C(CCC(N)=O)NC(=O)C(CC(N)=O)NC(=O)C(NC(=O)C(N)CC=1C=CC=CC=1)C(C)C)CC1=CN=CN1 NOESYZHRGYRDHS-UHFFFAOYSA-N 0.000 description 24
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 20
- WQZGKKKJIJFFOK-GASJEMHNSA-N Glucose Natural products OC[C@H]1OC(O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-GASJEMHNSA-N 0.000 description 17
- 239000008103 glucose Substances 0.000 description 17
- 102000004877 Insulin Human genes 0.000 description 12
- 108090001061 Insulin Proteins 0.000 description 12
- 229940125396 insulin Drugs 0.000 description 12
- KRKNYBCHXYNGOX-UHFFFAOYSA-N citric acid Chemical compound OC(=O)CC(O)(C(O)=O)CC(O)=O KRKNYBCHXYNGOX-UHFFFAOYSA-N 0.000 description 9
- 235000017471 coenzyme Q10 Nutrition 0.000 description 9
- 238000009472 formulation Methods 0.000 description 9
- CIWBSHSKHKDKBQ-JLAZNSOCSA-N Ascorbic acid Chemical compound OC[C@H](O)[C@H]1OC(=O)C(O)=C1O CIWBSHSKHKDKBQ-JLAZNSOCSA-N 0.000 description 8
- HVYWMOMLDIMFJA-DPAQBDIFSA-N cholesterol Chemical compound C1C=C2C[C@@H](O)CC[C@]2(C)[C@@H]2[C@@H]1[C@@H]1CC[C@H]([C@H](C)CCCC(C)C)[C@@]1(C)CC2 HVYWMOMLDIMFJA-DPAQBDIFSA-N 0.000 description 8
- 230000000694 effects Effects 0.000 description 8
- 239000003925 fat Substances 0.000 description 8
- 235000019197 fats Nutrition 0.000 description 8
- 239000002775 capsule Substances 0.000 description 7
- 229940079593 drug Drugs 0.000 description 7
- 239000003814 drug Substances 0.000 description 7
- 238000000855 fermentation Methods 0.000 description 7
- 230000004151 fermentation Effects 0.000 description 7
- 239000000796 flavoring agent Substances 0.000 description 7
- 235000019634 flavors Nutrition 0.000 description 7
- 239000012669 liquid formulation Substances 0.000 description 7
- 239000000843 powder Substances 0.000 description 7
- 235000020357 syrup Nutrition 0.000 description 7
- 239000006188 syrup Substances 0.000 description 7
- 238000004898 kneading Methods 0.000 description 6
- 150000002632 lipids Chemical class 0.000 description 6
- 235000013336 milk Nutrition 0.000 description 6
- 239000008267 milk Substances 0.000 description 6
- 210000004080 milk Anatomy 0.000 description 6
- 239000003381 stabilizer Substances 0.000 description 6
- 108010007622 LDL Lipoproteins Proteins 0.000 description 5
- 102000007330 LDL Lipoproteins Human genes 0.000 description 5
- 230000009471 action Effects 0.000 description 5
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 description 5
- 230000004190 glucose uptake Effects 0.000 description 5
- 230000002641 glycemic effect Effects 0.000 description 5
- 238000003756 stirring Methods 0.000 description 5
- 235000013618 yogurt Nutrition 0.000 description 5
- GVJHHUAWPYXKBD-UHFFFAOYSA-N (±)-α-Tocopherol Chemical compound OC1=C(C)C(C)=C2OC(CCCC(C)CCCC(C)CCCC(C)C)(C)CCC2=C1C GVJHHUAWPYXKBD-UHFFFAOYSA-N 0.000 description 4
- 108010010803 Gelatin Proteins 0.000 description 4
- 108010010234 HDL Lipoproteins Proteins 0.000 description 4
- 102000015779 HDL Lipoproteins Human genes 0.000 description 4
- 206010022489 Insulin Resistance Diseases 0.000 description 4
- 240000004808 Saccharomyces cerevisiae Species 0.000 description 4
- 239000000654 additive Substances 0.000 description 4
- 230000000996 additive effect Effects 0.000 description 4
- 239000003472 antidiabetic agent Substances 0.000 description 4
- 239000008280 blood Substances 0.000 description 4
- 210000004369 blood Anatomy 0.000 description 4
- 235000012000 cholesterol Nutrition 0.000 description 4
- 239000003086 colorant Substances 0.000 description 4
- 235000005911 diet Nutrition 0.000 description 4
- 230000037213 diet Effects 0.000 description 4
- 201000010099 disease Diseases 0.000 description 4
- 238000010304 firing Methods 0.000 description 4
- 235000013312 flour Nutrition 0.000 description 4
- 239000008273 gelatin Substances 0.000 description 4
- 229920000159 gelatin Polymers 0.000 description 4
- 239000007903 gelatin capsule Substances 0.000 description 4
- 235000019322 gelatine Nutrition 0.000 description 4
- 235000011852 gelatine desserts Nutrition 0.000 description 4
- 235000015243 ice cream Nutrition 0.000 description 4
- HQKMJHAJHXVSDF-UHFFFAOYSA-L magnesium stearate Chemical compound [Mg+2].CCCCCCCCCCCCCCCCCC([O-])=O.CCCCCCCCCCCCCCCCCC([O-])=O HQKMJHAJHXVSDF-UHFFFAOYSA-L 0.000 description 4
- 150000003839 salts Chemical class 0.000 description 4
- 235000020183 skimmed milk Nutrition 0.000 description 4
- 235000014214 soft drink Nutrition 0.000 description 4
- 208000002249 Diabetes Complications Diseases 0.000 description 3
- PEDCQBHIVMGVHV-UHFFFAOYSA-N Glycerine Chemical compound OCC(O)CO PEDCQBHIVMGVHV-UHFFFAOYSA-N 0.000 description 3
- 229920002472 Starch Polymers 0.000 description 3
- 239000003963 antioxidant agent Substances 0.000 description 3
- 235000006708 antioxidants Nutrition 0.000 description 3
- 235000010323 ascorbic acid Nutrition 0.000 description 3
- 229960005070 ascorbic acid Drugs 0.000 description 3
- 239000011668 ascorbic acid Substances 0.000 description 3
- 230000008901 benefit Effects 0.000 description 3
- 239000003795 chemical substances by application Substances 0.000 description 3
- 150000001875 compounds Chemical class 0.000 description 3
- 238000001816 cooling Methods 0.000 description 3
- 230000007812 deficiency Effects 0.000 description 3
- 230000018109 developmental process Effects 0.000 description 3
- 235000015203 fruit juice Nutrition 0.000 description 3
- 201000001421 hyperglycemia Diseases 0.000 description 3
- 230000003914 insulin secretion Effects 0.000 description 3
- 210000004185 liver Anatomy 0.000 description 3
- 230000010534 mechanism of action Effects 0.000 description 3
- 210000003205 muscle Anatomy 0.000 description 3
- 230000036542 oxidative stress Effects 0.000 description 3
- 235000014594 pastries Nutrition 0.000 description 3
- 230000000750 progressive effect Effects 0.000 description 3
- WXMKPNITSTVMEF-UHFFFAOYSA-M sodium benzoate Chemical compound [Na+].[O-]C(=O)C1=CC=CC=C1 WXMKPNITSTVMEF-UHFFFAOYSA-M 0.000 description 3
- 235000010234 sodium benzoate Nutrition 0.000 description 3
- 239000004299 sodium benzoate Substances 0.000 description 3
- 239000008107 starch Substances 0.000 description 3
- 235000019698 starch Nutrition 0.000 description 3
- 230000002195 synergetic effect Effects 0.000 description 3
- GHOKWGTUZJEAQD-ZETCQYMHSA-N (D)-(+)-Pantothenic acid Chemical compound OCC(C)(C)[C@@H](O)C(=O)NCCC(O)=O GHOKWGTUZJEAQD-ZETCQYMHSA-N 0.000 description 2
- AZQWKYJCGOJGHM-UHFFFAOYSA-N 1,4-benzoquinone Chemical compound O=C1C=CC(=O)C=C1 AZQWKYJCGOJGHM-UHFFFAOYSA-N 0.000 description 2
- ZKHQWZAMYRWXGA-KQYNXXCUSA-J ATP(4-) Chemical compound C1=NC=2C(N)=NC=NC=2N1[C@@H]1O[C@H](COP([O-])(=O)OP([O-])(=O)OP([O-])([O-])=O)[C@@H](O)[C@H]1O ZKHQWZAMYRWXGA-KQYNXXCUSA-J 0.000 description 2
- ZKHQWZAMYRWXGA-UHFFFAOYSA-N Adenosine triphosphate Natural products C1=NC=2C(N)=NC=NC=2N1C1OC(COP(O)(=O)OP(O)(=O)OP(O)(O)=O)C(O)C1O ZKHQWZAMYRWXGA-UHFFFAOYSA-N 0.000 description 2
- 208000017667 Chronic Disease Diseases 0.000 description 2
- 235000005979 Citrus limon Nutrition 0.000 description 2
- 244000131522 Citrus pyriformis Species 0.000 description 2
- ACTIUHUUMQJHFO-UHFFFAOYSA-N Coenzym Q10 Natural products COC1=C(OC)C(=O)C(CC=C(C)CCC=C(C)CCC=C(C)CCC=C(C)CCC=C(C)CCC=C(C)CCC=C(C)CCC=C(C)CCC=C(C)CCC=C(C)C)=C(C)C1=O ACTIUHUUMQJHFO-UHFFFAOYSA-N 0.000 description 2
- 206010012655 Diabetic complications Diseases 0.000 description 2
- 208000035150 Hypercholesterolemia Diseases 0.000 description 2
- QOEHNLSDMADWEF-UHFFFAOYSA-N I-Dotriacontanol Chemical compound CCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCO QOEHNLSDMADWEF-UHFFFAOYSA-N 0.000 description 2
- 235000019502 Orange oil Nutrition 0.000 description 2
- 208000001280 Prediabetic State Diseases 0.000 description 2
- 241000700159 Rattus Species 0.000 description 2
- 244000269722 Thea sinensis Species 0.000 description 2
- 108010062497 VLDL Lipoproteins Proteins 0.000 description 2
- 229930003427 Vitamin E Natural products 0.000 description 2
- 210000001789 adipocyte Anatomy 0.000 description 2
- 210000000577 adipose tissue Anatomy 0.000 description 2
- 230000003078 antioxidant effect Effects 0.000 description 2
- 235000014121 butter Nutrition 0.000 description 2
- ADRVNXBAWSRFAJ-UHFFFAOYSA-N catechin Natural products OC1Cc2cc(O)cc(O)c2OC1c3ccc(O)c(O)c3 ADRVNXBAWSRFAJ-UHFFFAOYSA-N 0.000 description 2
- 235000005487 catechin Nutrition 0.000 description 2
- 210000004027 cell Anatomy 0.000 description 2
- 239000001913 cellulose Chemical class 0.000 description 2
- 235000010980 cellulose Nutrition 0.000 description 2
- 229920002678 cellulose Chemical class 0.000 description 2
- 235000013339 cereals Nutrition 0.000 description 2
- 238000004040 coloring Methods 0.000 description 2
- 208000029078 coronary artery disease Diseases 0.000 description 2
- 239000006071 cream Substances 0.000 description 2
- 230000007423 decrease Effects 0.000 description 2
- 230000007547 defect Effects 0.000 description 2
- 239000000839 emulsion Substances 0.000 description 2
- 150000002191 fatty alcohols Chemical class 0.000 description 2
- 230000006870 function Effects 0.000 description 2
- WIGCFUFOHFEKBI-UHFFFAOYSA-N gamma-tocopherol Natural products CC(C)CCCC(C)CCCC(C)CCCC1CCC2C(C)C(O)C(C)C(C)C2O1 WIGCFUFOHFEKBI-UHFFFAOYSA-N 0.000 description 2
- 235000009569 green tea Nutrition 0.000 description 2
- ULCZGKYHRYJXAU-UHFFFAOYSA-N heptacosan-1-ol Chemical compound CCCCCCCCCCCCCCCCCCCCCCCCCCCO ULCZGKYHRYJXAU-UHFFFAOYSA-N 0.000 description 2
- IRHTZOCLLONTOC-UHFFFAOYSA-N hexacosan-1-ol Chemical compound CCCCCCCCCCCCCCCCCCCCCCCCCCO IRHTZOCLLONTOC-UHFFFAOYSA-N 0.000 description 2
- 235000019359 magnesium stearate Nutrition 0.000 description 2
- 235000020786 mineral supplement Nutrition 0.000 description 2
- 229940029985 mineral supplement Drugs 0.000 description 2
- 235000020772 multivitamin supplement Nutrition 0.000 description 2
- CNNRPFQICPFDPO-UHFFFAOYSA-N octacosan-1-ol Chemical compound CCCCCCCCCCCCCCCCCCCCCCCCCCCCO CNNRPFQICPFDPO-UHFFFAOYSA-N 0.000 description 2
- 239000010502 orange oil Substances 0.000 description 2
- 230000003647 oxidation Effects 0.000 description 2
- 238000007254 oxidation reaction Methods 0.000 description 2
- 239000001814 pectin Substances 0.000 description 2
- 235000010987 pectin Nutrition 0.000 description 2
- 229920001277 pectin Polymers 0.000 description 2
- 230000000144 pharmacologic effect Effects 0.000 description 2
- 230000000291 postprandial effect Effects 0.000 description 2
- 239000000126 substance Substances 0.000 description 2
- 230000009469 supplementation Effects 0.000 description 2
- 208000011580 syndromic disease Diseases 0.000 description 2
- 238000002560 therapeutic procedure Methods 0.000 description 2
- REZQBEBOWJAQKS-UHFFFAOYSA-N triacontan-1-ol Chemical compound CCCCCCCCCCCCCCCCCCCCCCCCCCCCCCO REZQBEBOWJAQKS-UHFFFAOYSA-N 0.000 description 2
- 235000019165 vitamin E Nutrition 0.000 description 2
- 229940046009 vitamin E Drugs 0.000 description 2
- 239000011709 vitamin E Substances 0.000 description 2
- 235000008939 whole milk Nutrition 0.000 description 2
- GVJHHUAWPYXKBD-IEOSBIPESA-N α-tocopherol Chemical compound OC1=C(C)C(C)=C2O[C@@](CCC[C@H](C)CCC[C@H](C)CCCC(C)C)(C)CCC2=C1C GVJHHUAWPYXKBD-IEOSBIPESA-N 0.000 description 2
- PFTAWBLQPZVEMU-DZGCQCFKSA-N (+)-catechin Chemical compound C1([C@H]2OC3=CC(O)=CC(O)=C3C[C@@H]2O)=CC=C(O)C(O)=C1 PFTAWBLQPZVEMU-DZGCQCFKSA-N 0.000 description 1
- DNIAPMSPPWPWGF-GSVOUGTGSA-N (R)-(-)-Propylene glycol Chemical compound C[C@@H](O)CO DNIAPMSPPWPWGF-GSVOUGTGSA-N 0.000 description 1
- OGYGFUAIIOPWQD-UHFFFAOYSA-N 1,3-thiazolidine Chemical compound C1CSCN1 OGYGFUAIIOPWQD-UHFFFAOYSA-N 0.000 description 1
- 229960002666 1-octacosanol Drugs 0.000 description 1
- WQNHWIYLCRZRLR-UHFFFAOYSA-N 2-(3-hydroxy-2,5-dioxooxolan-3-yl)acetic acid Chemical compound OC(=O)CC1(O)CC(=O)OC1=O WQNHWIYLCRZRLR-UHFFFAOYSA-N 0.000 description 1
- TVEXGJYMHHTVKP-UHFFFAOYSA-N 6-oxabicyclo[3.2.1]oct-3-en-7-one Chemical compound C1C2C(=O)OC1C=CC2 TVEXGJYMHHTVKP-UHFFFAOYSA-N 0.000 description 1
- 229940077274 Alpha glucosidase inhibitor Drugs 0.000 description 1
- 201000001320 Atherosclerosis Diseases 0.000 description 1
- 229940123208 Biguanide Drugs 0.000 description 1
- JCTHECMTHPMGHF-UHFFFAOYSA-N C1CSSC1.CC=CCC(O)=O Chemical compound C1CSSC1.CC=CCC(O)=O JCTHECMTHPMGHF-UHFFFAOYSA-N 0.000 description 1
- 208000024172 Cardiovascular disease Diseases 0.000 description 1
- GHOKWGTUZJEAQD-UHFFFAOYSA-N Chick antidermatitis factor Natural products OCC(C)(C)C(O)C(=O)NCCC(O)=O GHOKWGTUZJEAQD-UHFFFAOYSA-N 0.000 description 1
- 229920002785 Croscarmellose sodium Polymers 0.000 description 1
- ZZZCUOFIHGPKAK-UHFFFAOYSA-N D-erythro-ascorbic acid Natural products OCC1OC(=O)C(O)=C1O ZZZCUOFIHGPKAK-UHFFFAOYSA-N 0.000 description 1
- 208000032928 Dyslipidaemia Diseases 0.000 description 1
- 102000002322 Egg Proteins Human genes 0.000 description 1
- 108010000912 Egg Proteins Proteins 0.000 description 1
- LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 description 1
- 208000031226 Hyperlipidaemia Diseases 0.000 description 1
- 206010020772 Hypertension Diseases 0.000 description 1
- 102000003746 Insulin Receptor Human genes 0.000 description 1
- 108010001127 Insulin Receptor Proteins 0.000 description 1
- 229940122355 Insulin sensitizer Drugs 0.000 description 1
- GUBGYTABKSRVRQ-QKKXKWKRSA-N Lactose Natural products OC[C@H]1O[C@@H](O[C@H]2[C@H](O)[C@@H](O)C(O)O[C@@H]2CO)[C@H](O)[C@@H](O)[C@H]1O GUBGYTABKSRVRQ-QKKXKWKRSA-N 0.000 description 1
- 208000017170 Lipid metabolism disease Diseases 0.000 description 1
- 102000004895 Lipoproteins Human genes 0.000 description 1
- 108090001030 Lipoproteins Proteins 0.000 description 1
- 206010054805 Macroangiopathy Diseases 0.000 description 1
- 208000002720 Malnutrition Diseases 0.000 description 1
- 241001465754 Metazoa Species 0.000 description 1
- 229920000168 Microcrystalline cellulose Polymers 0.000 description 1
- GXCLVBGFBYZDAG-UHFFFAOYSA-N N-[2-(1H-indol-3-yl)ethyl]-N-methylprop-2-en-1-amine Chemical compound CN(CCC1=CNC2=C1C=CC=C2)CC=C GXCLVBGFBYZDAG-UHFFFAOYSA-N 0.000 description 1
- 108010016731 PPAR gamma Proteins 0.000 description 1
- 102000003728 Peroxisome Proliferator-Activated Receptors Human genes 0.000 description 1
- 108090000029 Peroxisome Proliferator-Activated Receptors Proteins 0.000 description 1
- 102100038825 Peroxisome proliferator-activated receptor gamma Human genes 0.000 description 1
- 244000018633 Prunus armeniaca Species 0.000 description 1
- 235000009827 Prunus armeniaca Nutrition 0.000 description 1
- 208000017442 Retinal disease Diseases 0.000 description 1
- 206010038923 Retinopathy Diseases 0.000 description 1
- 240000000111 Saccharum officinarum Species 0.000 description 1
- 235000007201 Saccharum officinarum Nutrition 0.000 description 1
- VYPSYNLAJGMNEJ-UHFFFAOYSA-N Silicium dioxide Chemical compound O=[Si]=O VYPSYNLAJGMNEJ-UHFFFAOYSA-N 0.000 description 1
- 229930006000 Sucrose Natural products 0.000 description 1
- CZMRCDWAGMRECN-UGDNZRGBSA-N Sucrose Chemical compound O[C@H]1[C@H](O)[C@@H](CO)O[C@@]1(CO)O[C@@H]1[C@H](O)[C@@H](O)[C@H](O)[C@@H](CO)O1 CZMRCDWAGMRECN-UGDNZRGBSA-N 0.000 description 1
- 229940100389 Sulfonylurea Drugs 0.000 description 1
- 208000007536 Thrombosis Diseases 0.000 description 1
- 229930003268 Vitamin C Natural products 0.000 description 1
- 229930003448 Vitamin K Natural products 0.000 description 1
- 230000005856 abnormality Effects 0.000 description 1
- DPXJVFZANSGRMM-UHFFFAOYSA-N acetic acid;2,3,4,5,6-pentahydroxyhexanal;sodium Chemical compound [Na].CC(O)=O.OCC(O)C(O)C(O)C(O)C=O DPXJVFZANSGRMM-UHFFFAOYSA-N 0.000 description 1
- 230000004913 activation Effects 0.000 description 1
- 239000013543 active substance Substances 0.000 description 1
- 238000009098 adjuvant therapy Methods 0.000 description 1
- 230000002411 adverse Effects 0.000 description 1
- 230000032683 aging Effects 0.000 description 1
- 239000000556 agonist Substances 0.000 description 1
- OENHQHLEOONYIE-UKMVMLAPSA-N all-trans beta-carotene Natural products CC=1CCCC(C)(C)C=1/C=C/C(/C)=C/C=C/C(/C)=C/C=C/C=C(C)C=CC=C(C)C=CC1=C(C)CCCC1(C)C OENHQHLEOONYIE-UKMVMLAPSA-N 0.000 description 1
- 239000003888 alpha glucosidase inhibitor Substances 0.000 description 1
- 229940087168 alpha tocopherol Drugs 0.000 description 1
- 238000010171 animal model Methods 0.000 description 1
- 230000000489 anti-atherogenic effect Effects 0.000 description 1
- 230000003178 anti-diabetic effect Effects 0.000 description 1
- 230000000923 atherogenic effect Effects 0.000 description 1
- 230000037208 balanced nutrition Effects 0.000 description 1
- 235000019046 balanced nutrition Nutrition 0.000 description 1
- 230000009286 beneficial effect Effects 0.000 description 1
- WQZGKKKJIJFFOK-VFUOTHLCSA-N beta-D-glucose Chemical compound OC[C@H]1O[C@@H](O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-VFUOTHLCSA-N 0.000 description 1
- TUPZEYHYWIEDIH-WAIFQNFQSA-N beta-carotene Natural products CC(=C/C=C/C=C(C)/C=C/C=C(C)/C=C/C1=C(C)CCCC1(C)C)C=CC=C(/C)C=CC2=CCCCC2(C)C TUPZEYHYWIEDIH-WAIFQNFQSA-N 0.000 description 1
- 235000013734 beta-carotene Nutrition 0.000 description 1
- 239000011648 beta-carotene Substances 0.000 description 1
- 229960002747 betacarotene Drugs 0.000 description 1
- 150000004283 biguanides Chemical class 0.000 description 1
- 230000008238 biochemical pathway Effects 0.000 description 1
- 230000015572 biosynthetic process Effects 0.000 description 1
- 238000009835 boiling Methods 0.000 description 1
- 235000008429 bread Nutrition 0.000 description 1
- 150000001720 carbohydrates Chemical class 0.000 description 1
- 235000014633 carbohydrates Nutrition 0.000 description 1
- 125000004432 carbon atom Chemical group C* 0.000 description 1
- 210000004413 cardiac myocyte Anatomy 0.000 description 1
- 239000003054 catalyst Substances 0.000 description 1
- 150000001765 catechin Chemical class 0.000 description 1
- 230000003915 cell function Effects 0.000 description 1
- MRQIXHXHHPWVIL-UHFFFAOYSA-N chembl1397023 Chemical compound OC1=CC=C2C=CC=CC2=C1N=NC1=CC=CC=C1 MRQIXHXHHPWVIL-UHFFFAOYSA-N 0.000 description 1
- 229950001002 cianidanol Drugs 0.000 description 1
- 229940110767 coenzyme Q10 Drugs 0.000 description 1
- 238000002648 combination therapy Methods 0.000 description 1
- 235000009508 confectionery Nutrition 0.000 description 1
- 235000014510 cooky Nutrition 0.000 description 1
- 229960001681 croscarmellose sodium Drugs 0.000 description 1
- 235000010947 crosslinked sodium carboxy methyl cellulose Nutrition 0.000 description 1
- 238000005520 cutting process Methods 0.000 description 1
- UFULAYFCSOUIOV-UHFFFAOYSA-N cysteamine Chemical compound NCCS UFULAYFCSOUIOV-UHFFFAOYSA-N 0.000 description 1
- 230000006378 damage Effects 0.000 description 1
- 230000003247 decreasing effect Effects 0.000 description 1
- 239000008367 deionised water Substances 0.000 description 1
- 229910021641 deionized water Inorganic materials 0.000 description 1
- 230000006866 deterioration Effects 0.000 description 1
- 230000006806 disease prevention Effects 0.000 description 1
- 208000035475 disorder Diseases 0.000 description 1
- 230000035622 drinking Effects 0.000 description 1
- 230000005584 early death Effects 0.000 description 1
- 235000006694 eating habits Nutrition 0.000 description 1
- 230000002526 effect on cardiovascular system Effects 0.000 description 1
- 230000000487 effect on differentiation Effects 0.000 description 1
- 235000013345 egg yolk Nutrition 0.000 description 1
- 210000002969 egg yolk Anatomy 0.000 description 1
- 235000013601 eggs Nutrition 0.000 description 1
- 239000003995 emulsifying agent Substances 0.000 description 1
- 230000008753 endothelial function Effects 0.000 description 1
- 230000037149 energy metabolism Effects 0.000 description 1
- 235000020774 essential nutrients Nutrition 0.000 description 1
- 150000002148 esters Chemical class 0.000 description 1
- 125000004494 ethyl ester group Chemical group 0.000 description 1
- 230000029142 excretion Effects 0.000 description 1
- 239000000945 filler Substances 0.000 description 1
- 235000011389 fruit/vegetable juice Nutrition 0.000 description 1
- 230000009229 glucose formation Effects 0.000 description 1
- 230000004153 glucose metabolism Effects 0.000 description 1
- 230000006377 glucose transport Effects 0.000 description 1
- 230000005484 gravity Effects 0.000 description 1
- 230000008821 health effect Effects 0.000 description 1
- 208000019622 heart disease Diseases 0.000 description 1
- 238000010438 heat treatment Methods 0.000 description 1
- 210000003494 hepatocyte Anatomy 0.000 description 1
- 238000000265 homogenisation Methods 0.000 description 1
- 230000001771 impaired effect Effects 0.000 description 1
- 230000002401 inhibitory effect Effects 0.000 description 1
- 229910052500 inorganic mineral Inorganic materials 0.000 description 1
- 230000002452 interceptive effect Effects 0.000 description 1
- 230000003834 intracellular effect Effects 0.000 description 1
- 208000017169 kidney disease Diseases 0.000 description 1
- 239000008101 lactose Substances 0.000 description 1
- 230000003902 lesion Effects 0.000 description 1
- XMGQYMWWDOXHJM-UHFFFAOYSA-N limonene Chemical compound CC(=C)C1CCC(C)=CC1 XMGQYMWWDOXHJM-UHFFFAOYSA-N 0.000 description 1
- 239000007788 liquid Substances 0.000 description 1
- 230000007774 longterm Effects 0.000 description 1
- 239000000314 lubricant Substances 0.000 description 1
- 230000007246 mechanism Effects 0.000 description 1
- 239000012528 membrane Substances 0.000 description 1
- 229960003151 mercaptamine Drugs 0.000 description 1
- 208000030159 metabolic disease Diseases 0.000 description 1
- 230000002503 metabolic effect Effects 0.000 description 1
- 230000007102 metabolic function Effects 0.000 description 1
- 230000004060 metabolic process Effects 0.000 description 1
- 125000002496 methyl group Chemical group [H]C([H])([H])* 0.000 description 1
- 235000019813 microcrystalline cellulose Nutrition 0.000 description 1
- 239000008108 microcrystalline cellulose Substances 0.000 description 1
- 229940016286 microcrystalline cellulose Drugs 0.000 description 1
- 239000011707 mineral Substances 0.000 description 1
- 210000003470 mitochondria Anatomy 0.000 description 1
- 230000005787 mitochondrial ATP synthesis coupled electron transport Effects 0.000 description 1
- 230000002438 mitochondrial effect Effects 0.000 description 1
- 238000002156 mixing Methods 0.000 description 1
- 201000001119 neuropathy Diseases 0.000 description 1
- 230000007823 neuropathy Effects 0.000 description 1
- 230000001019 normoglycemic effect Effects 0.000 description 1
- 235000018343 nutrient deficiency Nutrition 0.000 description 1
- 235000016709 nutrition Nutrition 0.000 description 1
- 238000011903 nutritional therapy Methods 0.000 description 1
- 239000003921 oil Substances 0.000 description 1
- 235000019198 oils Nutrition 0.000 description 1
- 239000007968 orange flavor Substances 0.000 description 1
- 210000000056 organ Anatomy 0.000 description 1
- 238000010422 painting Methods 0.000 description 1
- 229940055726 pantothenic acid Drugs 0.000 description 1
- 235000019161 pantothenic acid Nutrition 0.000 description 1
- 239000011713 pantothenic acid Substances 0.000 description 1
- 230000001991 pathophysiological effect Effects 0.000 description 1
- 230000037361 pathway Effects 0.000 description 1
- 208000033808 peripheral neuropathy Diseases 0.000 description 1
- SHUZOJHMOBOZST-UHFFFAOYSA-N phylloquinone Natural products CC(C)CCCCC(C)CCC(C)CCCC(=CCC1=C(C)C(=O)c2ccccc2C1=O)C SHUZOJHMOBOZST-UHFFFAOYSA-N 0.000 description 1
- 210000000229 preadipocyte Anatomy 0.000 description 1
- 238000002360 preparation method Methods 0.000 description 1
- 230000003449 preventive effect Effects 0.000 description 1
- 230000007425 progressive decline Effects 0.000 description 1
- 235000018102 proteins Nutrition 0.000 description 1
- 102000004169 proteins and genes Human genes 0.000 description 1
- 108090000623 proteins and genes Proteins 0.000 description 1
- 239000003642 reactive oxygen metabolite Substances 0.000 description 1
- 239000011435 rock Substances 0.000 description 1
- 230000001235 sensitizing effect Effects 0.000 description 1
- 210000002966 serum Anatomy 0.000 description 1
- 230000019491 signal transduction Effects 0.000 description 1
- 229910052814 silicon oxide Inorganic materials 0.000 description 1
- 235000020374 simple syrup Nutrition 0.000 description 1
- 210000002027 skeletal muscle Anatomy 0.000 description 1
- 230000000087 stabilizing effect Effects 0.000 description 1
- 230000000638 stimulation Effects 0.000 description 1
- 208000023516 stroke disease Diseases 0.000 description 1
- 239000005720 sucrose Substances 0.000 description 1
- 239000000725 suspension Substances 0.000 description 1
- 238000003786 synthesis reaction Methods 0.000 description 1
- 230000001225 therapeutic effect Effects 0.000 description 1
- 229960000984 tocofersolan Drugs 0.000 description 1
- 150000003626 triacylglycerols Chemical class 0.000 description 1
- 235000015112 vegetable and seed oil Nutrition 0.000 description 1
- 239000008158 vegetable oil Substances 0.000 description 1
- 239000012178 vegetable wax Substances 0.000 description 1
- 229940088594 vitamin Drugs 0.000 description 1
- 229930003231 vitamin Natural products 0.000 description 1
- 235000013343 vitamin Nutrition 0.000 description 1
- 239000011782 vitamin Substances 0.000 description 1
- 235000019154 vitamin C Nutrition 0.000 description 1
- 239000011718 vitamin C Substances 0.000 description 1
- 235000019168 vitamin K Nutrition 0.000 description 1
- 239000011712 vitamin K Substances 0.000 description 1
- 150000003721 vitamin K derivatives Chemical class 0.000 description 1
- 229940046010 vitamin k Drugs 0.000 description 1
- 239000001993 wax Substances 0.000 description 1
- 239000002076 α-tocopherol Substances 0.000 description 1
- 235000004835 α-tocopherol Nutrition 0.000 description 1
- OENHQHLEOONYIE-JLTXGRSLSA-N β-Carotene Chemical compound CC=1CCCC(C)(C)C=1\C=C\C(\C)=C\C=C\C(\C)=C\C=C\C=C(/C)\C=C\C=C(/C)\C=C\C1=C(C)CCCC1(C)C OENHQHLEOONYIE-JLTXGRSLSA-N 0.000 description 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
- A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
-
- A—HUMAN NECESSITIES
- A21—BAKING; EDIBLE DOUGHS
- A21D—TREATMENT, e.g. PRESERVATION, OF FLOUR OR DOUGH, e.g. BY ADDITION OF MATERIALS; BAKING; BAKERY PRODUCTS; PRESERVATION THEREOF
- A21D2/00—Treatment of flour or dough by adding materials thereto before or during baking
- A21D2/08—Treatment of flour or dough by adding materials thereto before or during baking by adding organic substances
- A21D2/14—Organic oxygen compounds
-
- A—HUMAN NECESSITIES
- A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
- A23C—DAIRY PRODUCTS, e.g. MILK, BUTTER OR CHEESE; MILK OR CHEESE SUBSTITUTES; MAKING THEREOF
- A23C9/00—Milk preparations; Milk powder or milk powder preparations
- A23C9/12—Fermented milk preparations; Treatment using microorganisms or enzymes
- A23C9/13—Fermented milk preparations; Treatment using microorganisms or enzymes using additives
-
- A—HUMAN NECESSITIES
- A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
- A23C—DAIRY PRODUCTS, e.g. MILK, BUTTER OR CHEESE; MILK OR CHEESE SUBSTITUTES; MAKING THEREOF
- A23C9/00—Milk preparations; Milk powder or milk powder preparations
- A23C9/12—Fermented milk preparations; Treatment using microorganisms or enzymes
- A23C9/13—Fermented milk preparations; Treatment using microorganisms or enzymes using additives
- A23C9/1307—Milk products or derivatives; Fruit or vegetable juices; Sugars, sugar alcohols, sweeteners; Oligosaccharides; Organic acids or salts thereof or acidifying agents; Flavours, dyes or pigments; Inert or aerosol gases; Carbonation methods
-
- A—HUMAN NECESSITIES
- A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
- A23C—DAIRY PRODUCTS, e.g. MILK, BUTTER OR CHEESE; MILK OR CHEESE SUBSTITUTES; MAKING THEREOF
- A23C9/00—Milk preparations; Milk powder or milk powder preparations
- A23C9/12—Fermented milk preparations; Treatment using microorganisms or enzymes
- A23C9/13—Fermented milk preparations; Treatment using microorganisms or enzymes using additives
- A23C9/1322—Inorganic compounds; Minerals, including organic salts thereof, oligo-elements; Amino-acids, peptides, protein-hydrolysates or derivatives; Nucleic acids or derivatives; Yeast extract or autolysate; Vitamins; Antibiotics; Bacteriocins
-
- A—HUMAN NECESSITIES
- A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
- A23G—COCOA; COCOA PRODUCTS, e.g. CHOCOLATE; SUBSTITUTES FOR COCOA OR COCOA PRODUCTS; CONFECTIONERY; CHEWING GUM; ICE-CREAM; PREPARATION THEREOF
- A23G3/00—Sweetmeats; Confectionery; Marzipan; Coated or filled products
- A23G3/34—Sweetmeats, confectionery or marzipan; Processes for the preparation thereof
- A23G3/36—Sweetmeats, confectionery or marzipan; Processes for the preparation thereof characterised by the composition containing organic or inorganic compounds
- A23G3/364—Sweetmeats, confectionery or marzipan; Processes for the preparation thereof characterised by the composition containing organic or inorganic compounds containing microorganisms or enzymes; containing paramedical or dietetical agents, e.g. vitamins
- A23G3/368—Sweetmeats, confectionery or marzipan; Processes for the preparation thereof characterised by the composition containing organic or inorganic compounds containing microorganisms or enzymes; containing paramedical or dietetical agents, e.g. vitamins containing vitamins, antibiotics
-
- A—HUMAN NECESSITIES
- A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
- A23G—COCOA; COCOA PRODUCTS, e.g. CHOCOLATE; SUBSTITUTES FOR COCOA OR COCOA PRODUCTS; CONFECTIONERY; CHEWING GUM; ICE-CREAM; PREPARATION THEREOF
- A23G3/00—Sweetmeats; Confectionery; Marzipan; Coated or filled products
- A23G3/34—Sweetmeats, confectionery or marzipan; Processes for the preparation thereof
- A23G3/36—Sweetmeats, confectionery or marzipan; Processes for the preparation thereof characterised by the composition containing organic or inorganic compounds
- A23G3/48—Sweetmeats, confectionery or marzipan; Processes for the preparation thereof characterised by the composition containing organic or inorganic compounds containing plants or parts thereof, e.g. fruits, seeds, extracts
-
- A—HUMAN NECESSITIES
- A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
- A23G—COCOA; COCOA PRODUCTS, e.g. CHOCOLATE; SUBSTITUTES FOR COCOA OR COCOA PRODUCTS; CONFECTIONERY; CHEWING GUM; ICE-CREAM; PREPARATION THEREOF
- A23G9/00—Frozen sweets, e.g. ice confectionery, ice-cream; Mixtures therefor
- A23G9/32—Frozen sweets, e.g. ice confectionery, ice-cream; Mixtures therefor characterised by the composition containing organic or inorganic compounds
- A23G9/36—Frozen sweets, e.g. ice confectionery, ice-cream; Mixtures therefor characterised by the composition containing organic or inorganic compounds containing microorganisms or enzymes; containing paramedical or dietetical agents, e.g. vitamins
- A23G9/366—Frozen sweets, e.g. ice confectionery, ice-cream; Mixtures therefor characterised by the composition containing organic or inorganic compounds containing microorganisms or enzymes; containing paramedical or dietetical agents, e.g. vitamins containing vitamins, antibiotics
-
- A—HUMAN NECESSITIES
- A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
- A23G—COCOA; COCOA PRODUCTS, e.g. CHOCOLATE; SUBSTITUTES FOR COCOA OR COCOA PRODUCTS; CONFECTIONERY; CHEWING GUM; ICE-CREAM; PREPARATION THEREOF
- A23G9/00—Frozen sweets, e.g. ice confectionery, ice-cream; Mixtures therefor
- A23G9/32—Frozen sweets, e.g. ice confectionery, ice-cream; Mixtures therefor characterised by the composition containing organic or inorganic compounds
- A23G9/42—Frozen sweets, e.g. ice confectionery, ice-cream; Mixtures therefor characterised by the composition containing organic or inorganic compounds containing plants or parts thereof, e.g. fruits, seeds, extracts
-
- A—HUMAN NECESSITIES
- A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
- A23L—FOODS, FOODSTUFFS, OR NON-ALCOHOLIC BEVERAGES, NOT COVERED BY SUBCLASSES A21D OR A23B-A23J; THEIR PREPARATION OR TREATMENT, e.g. COOKING, MODIFICATION OF NUTRITIVE QUALITIES, PHYSICAL TREATMENT; PRESERVATION OF FOODS OR FOODSTUFFS, IN GENERAL
- A23L2/00—Non-alcoholic beverages; Dry compositions or concentrates therefor; Their preparation
- A23L2/02—Non-alcoholic beverages; Dry compositions or concentrates therefor; Their preparation containing fruit or vegetable juices
-
- A—HUMAN NECESSITIES
- A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
- A23L—FOODS, FOODSTUFFS, OR NON-ALCOHOLIC BEVERAGES, NOT COVERED BY SUBCLASSES A21D OR A23B-A23J; THEIR PREPARATION OR TREATMENT, e.g. COOKING, MODIFICATION OF NUTRITIVE QUALITIES, PHYSICAL TREATMENT; PRESERVATION OF FOODS OR FOODSTUFFS, IN GENERAL
- A23L2/00—Non-alcoholic beverages; Dry compositions or concentrates therefor; Their preparation
- A23L2/52—Adding ingredients
-
- A—HUMAN NECESSITIES
- A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
- A23L—FOODS, FOODSTUFFS, OR NON-ALCOHOLIC BEVERAGES, NOT COVERED BY SUBCLASSES A21D OR A23B-A23J; THEIR PREPARATION OR TREATMENT, e.g. COOKING, MODIFICATION OF NUTRITIVE QUALITIES, PHYSICAL TREATMENT; PRESERVATION OF FOODS OR FOODSTUFFS, IN GENERAL
- A23L33/00—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof
- A23L33/10—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof using additives
- A23L33/105—Plant extracts, their artificial duplicates or their derivatives
-
- A—HUMAN NECESSITIES
- A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
- A23L—FOODS, FOODSTUFFS, OR NON-ALCOHOLIC BEVERAGES, NOT COVERED BY SUBCLASSES A21D OR A23B-A23J; THEIR PREPARATION OR TREATMENT, e.g. COOKING, MODIFICATION OF NUTRITIVE QUALITIES, PHYSICAL TREATMENT; PRESERVATION OF FOODS OR FOODSTUFFS, IN GENERAL
- A23L33/00—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof
- A23L33/10—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof using additives
- A23L33/105—Plant extracts, their artificial duplicates or their derivatives
- A23L33/11—Plant sterols or derivatives thereof, e.g. phytosterols
-
- A—HUMAN NECESSITIES
- A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
- A23L—FOODS, FOODSTUFFS, OR NON-ALCOHOLIC BEVERAGES, NOT COVERED BY SUBCLASSES A21D OR A23B-A23J; THEIR PREPARATION OR TREATMENT, e.g. COOKING, MODIFICATION OF NUTRITIVE QUALITIES, PHYSICAL TREATMENT; PRESERVATION OF FOODS OR FOODSTUFFS, IN GENERAL
- A23L33/00—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof
- A23L33/10—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof using additives
- A23L33/15—Vitamins
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/12—Ketones
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/16—Amides, e.g. hydroxamic acids
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
- A61K31/19—Carboxylic acids, e.g. valproic acid
- A61K31/20—Carboxylic acids, e.g. valproic acid having a carboxyl group bound to a chain of seven or more carbon atoms, e.g. stearic, palmitic, arachidic acids
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/335—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
- A61K31/35—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having six-membered rings with one oxygen as the only ring hetero atom
- A61K31/352—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having six-membered rings with one oxygen as the only ring hetero atom condensed with carbocyclic rings, e.g. methantheline
- A61K31/353—3,4-Dihydrobenzopyrans, e.g. chroman, catechin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/38—Heterocyclic compounds having sulfur as a ring hetero atom
- A61K31/385—Heterocyclic compounds having sulfur as a ring hetero atom having two or more sulfur atoms in the same ring
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/56—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids
- A61K31/575—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids substituted in position 17 beta by a chain of three or more carbon atoms, e.g. cholane, cholestane, ergosterol, sitosterol
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/04—Anorexiants; Antiobesity agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
- A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
-
- A—HUMAN NECESSITIES
- A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
- A23V—INDEXING SCHEME RELATING TO FOODS, FOODSTUFFS OR NON-ALCOHOLIC BEVERAGES AND LACTIC OR PROPIONIC ACID BACTERIA USED IN FOODSTUFFS OR FOOD PREPARATION
- A23V2002/00—Food compositions, function of food ingredients or processes for food or foodstuffs
Abstract
Description
EGCGとパンテチン;
EGCGとフィタン酸;
パンテチンとフィタン酸;
EGCGとコエンザイムQ−10;
EGCGとフィタン酸とコエンザイムQ−10;
EGCGとフィタン酸とパンテチン;並びに
EGCGとフィタン酸とパンテチンとコエンザイムQ−10、
との組合せを含む。最も好ましいのは、EGCGとパンテチン又はフィタン酸との組合せ、並びにパンテチンとフィタン酸との組合せである。
EGCG:20〜2100mg/日
パンテチン:70〜3500mg/日
フィタン酸:70〜7000mg/日
コエンザイムQ−10:1〜2100mg/日
リポ酸:20〜2100mg/日
ポリコサノール:0.15〜100mg/日
軟ゼラチンカプセル剤
軟ソフトゼラチンカプセル剤を、以下に明記した成分を用い、従来の手順によって製造した。
活性成分:EGCG300mg パンテチン100mg
他の成分:グリセロール、水、ゼラチン、植物油
硬ゼラチンカプセル剤
硬ゼラチンカプセル剤を、以下に明記した成分を用い、従来の手順によって製造した。
活性成分:EGCG150mg パンテチン100mg
他の成分
充填剤:ラクトース又はセルロース又はセルロース誘導体 十分な量
滑剤:必要ならばステアリン酸マグネシウム(0.5%)
錠剤
錠剤を、以下に明記した成分を用い、従来の手順によって製造した。
活性成分:EGCG100mg パンテチン50mg
他の成分:微結晶セルロース、酸化ケイ素、ステアリン酸マグネシウム、クロスカルメロースナトリウム
果汁30%のソフトドリンク
通常の一杯:240ml
活性成分:
EGCGと、パンテチン、コエンザイムQ−10、フィタン酸及びリポ酸から選択される1種以上の追加の成分とを、この食品に混和した。
パンテチン:20〜800mg/杯
EGCG:5〜500mg/杯
フィタン酸:20〜2000mg/杯
コエンザイムQ−10:1〜400mg/杯
リポ酸:5〜500mg/杯
ポリコサノール:0.1〜20mg/杯
濃縮果汁及び水溶性香味料
[g]
60.3°Brix、5.15%酸性度 657.99
濃縮レモン
43.5°Brix、32.7%酸性度 95.96
水溶性オレンジ香味料 13.43
水溶性アプリコット香味料 6.71
水 26.46
β−カロテン10%CWS 0.89
水 67.65
アスコルビン酸 4.11
無水クエン酸 0.69
水 43.18
ペクチン 0.20
安息香酸ナトリウム 2.74
水 65.60
脂溶性オレンジ香味料 0.34
蒸留オレンジ油 0.34
上記の濃度の活性成分(これは、上述の活性成分:EGCG並びに、パンテチン、コエンザイムQ−10、リポ酸、ポリコサノール及び/又はフィタン酸のうちの1種以上を意味する)
[g]
ソフトドリンク化合物 74.50
水 50.00
シュガーシロップ60°Brix 150.00
安息香酸ナトリウムを用いる代わりに、飲料を低温殺菌してもよい。飲料を炭酸化(carbonised)してもよい。
5種シリアルブレッド
通常の一枚:50g
活性成分:
EGCGと、パンテチン、コエンザイムQ−10、フィタン酸及びリポ酸から選択される1種以上の追加の成分とを、この食品に混和した。
パンテチン:20〜800mg/枚
EGCG:5〜500mg/枚
フィタン酸:20〜2000mg/枚
リポ酸:5〜500mg/枚
コエンザイムQ−10:1〜400mg/枚
ポリコサノール:0.1〜20mg/枚
5種シリアル粉 56.8
水 39.8
酵母 2.3
塩 1.1
酵母を水の一部に溶解した。全ての成分を一緒に混合して、練り生地を形成させた。塩を混練時間の終了時に添加した。発酵の後、練り生地に再作業(reworked)をして分割した後、ローフを形成させた。焼く前にローフの表面に水をブラシで付けて、小麦粉を振りかけた。
混錬:
らせん混錬装置 目盛り1で4分、目盛り2で5分
練り生地の最終発酵 60分
練り生地の温度 22〜24℃
最終発酵時間 30分
オーブン: ダッチ式オーブン
焼成温度: 250/220℃
焼成時間: 50〜60分
ミラノクッキー
通常の一枚:30g
活性成分:
EGCGと、パンテチン、コエンザイムQ−10、フィタン酸及びリポ酸から選択される1種以上の追加の成分とを、この食品に混和した。
パンテチン:20〜800mg/枚
EGCG:5〜500mg/枚
フィタン酸:20〜2000mg/枚
コエンザイムQ−10:1〜400mg/枚
リポ酸:5〜500mg/枚
ポリコサノール:0.1〜20mg/枚
小麦粉 550型 41.0
砂糖 20.5
脂肪/バター 20.5
全卵(液体) 18.0
レモン香味料 十分な量
ベーキング剤 十分な量
オーブン: ファン式オーブン
焼成温度: 180℃
焼成時間: 15分
トースト
通常の一枚:100g
活性成分:
EGCGと、パンテチン、コエンザイムQ−10、フィタン酸及びリポ酸から選択される1種以上の追加の成分とを、この食品に混和した。
パンテチン:20〜800mg/枚
EGCG:5〜500mg/枚
フィタン酸:20〜2000mg/枚
コエンザイムQ−10:1〜400mg/枚
リポ酸:5〜500mg/枚
ポリコサノール:0.1〜20mg/枚
小麦粉 550型 55.4
水 33.2
酵母 2.8
塩 1.1
脂肪/バター 5.5
麦芽 0.6
乳化剤、ベーキング剤 1.4
混錬:
らせん混錬装置: 目盛り1で5〜6分、目盛り2で3〜4分
練り生地の最終発酵: 無し
練り生地の温度: 22〜24℃
最終発酵時間: 40分
オーブン: ダッチ式オーブン
焼成温度: 220℃
焼成時間: 35〜40分
ヨーグルト 固形タイプ、脂肪分3.5%
通常の一杯:225g
活性成分:
EGCGと、パンテチン、EGCG、フィタン酸及びリポ酸から選択される1種以上の追加の成分とを、この食品に混和した。
コエンザイムQ−10:1〜400mg/杯
パンテチン:20〜800mg/杯
EGCG:5〜500mg/杯
フィタン酸:20〜2000mg/杯
リポ酸:5〜500mg/杯
ポリコサノール:0.1〜20mg/杯
フルファットミルク(脂肪分3.8%) 90.5
スキムミルク粉 2.0
砂糖 5.0
培養物 2.5
ヨーグルト、撹拌タイプ、脂肪分3.5%
通常の一杯:225g
EGCGと、パンテチン、コエンザイムQ−10、フィタン酸及びリポ酸から選択される1種以上の追加の成分とを、この食品に混和した。
コエンザイムQ−10:1〜400mg/杯
パンテチン:20〜800mg/杯
EGCG:5〜500mg/杯
フィタン酸:20〜2000mg/杯
リポ酸:5〜500mg/杯
ポリコサノール:0.1〜20mg/杯
フルファットミルク(脂肪分3.8%) 90.2
スキムミルク粉 2.0
安定化剤 0.3
砂糖 5.0
培養物 2.5
アイスクリーム、脂肪分8%
通常の一杯:85g
活性成分:
EGCGと、パンテチン、コエンザイムQ−10、フィタン酸及びリポ酸から選択される1種以上の追加の成分とを、この食品に混和した。
コエンザイムQ−10:1〜400mg/杯
パンテチン:20〜800mg/杯
EGCG:5〜500mg/杯
フィタン酸:20〜2000mg/杯
リポ酸:5〜500mg/杯
ポリコサノール:0.1〜20mg/杯
牛乳(脂肪分3.7%) 600.00
クリーム(脂肪分35%) 166.00
スキムミルク粉 49.10
砂糖 109.00
グルコースシロップ80% 70.00
アイスクリーム安定化剤 5.00
香味料 十分な量
着色料 十分な量
ワインガム
活性成分:
EGCGと、パンテチン、EGCG、フィタン酸及びリポ酸から選択される1種以上の追加の成分とを、この食品に混和した。
コエンザイムQ−10:1〜400mg/30g
パンテチン:20〜800mg/30g
EGCG:5〜500mg/30g
フィタン酸:20〜2000mg/30g
リポ酸:5〜500mg/30g
ポリコサノール:0.1〜20mg/杯
ゼラチン、ブルーム200 80.0
水I 125.0
氷砂糖 290.0
水II 120.0
グルコースシロップDE38 390.0
クエン酸 10.0
香味料 2.0
着色料 十分な量
収量(おおよそ) 1000.0
Claims (27)
- EGCG、パンテチン又はその代謝産物、フィタン酸、リポ酸、ポリコサノール及びコエンザイムQ−10から選択される少なくとも2種の成分を含む、前糖尿病の個人における2型糖尿病、又は耐糖能障害(IGT)若しくは肥満症を、治療又は予防するための組成物。
- EGCG、パンテチン又はその代謝産物、フィタン酸、リポ酸及びコエンザイムQ−10から選択される少なくとも2種の成分を含む、前糖尿病の個人における2型糖尿病、又は耐糖能障害(IGT)若しくは肥満症を、治療又は予防するための組成物。
- EGCG及びパンテチンが存在する、請求項1又は2記載の組成物。
- EGCG及びフィタン酸が存在する、請求項1又は2記載の組成物。
- パンテチン及びフィタン酸が存在する、請求項1又は2記載の組成物。
- 日用量0.3mg/kg体重〜約30mg/kg体重を患者に投与するのに十分な量のEGCGを含有する、請求項3又は4記載の組成物。
- 日用量1mg/kg体重〜約50mg/kg体重を患者に投与するのに十分な量のパンテチンを含有する、請求項3又は5記載の組成物。
- 日用量1mg/kg体重〜約100mg/kg体重を患者に投与するのに十分な量のフィタン酸を含有する、請求項4又は5記載の組成物。
- リポ酸が存在する、請求項1〜8のいずれか1項記載の組成物。
- リポ酸が、日用量0.3mg/kg体重〜約30mg/kg体重を患者に投与するのに十分な量で存在する、請求項9記載の組成物。
- コエンザイムQ−10が存在する、請求項1〜10のいずれか1項記載の組成物。
- コエンザイムQ−10が、日用量0.01mg/kg体重〜約30mg/kg体重を患者に投与するのに十分な量で存在する、請求項11記載の組成物。
- ポリコサノールが存在する、請求項1〜12のいずれか1項記載の組成物。
- ポリコサノールが、日用量0.002mg/kg体重〜約1.5mg/kg体重を患者に投与するのに十分な量で存在する、請求項13記載の組成物。
- 投与単位形態である、請求項1〜14のいずれか1項記載の組成物。
- 投与単位形態が固形投与単位形態である、請求項15記載の組成物。
- 投与単位形態が、EGCG約10mg〜約500mgを含有する、請求項16記載の組成物。
- 投与単位形態が、パンテチン約20mg〜約1000mgを含有する、請求項16記載の組成物。
- 投与単位形態が、フィタン酸約30mg〜約500mgを含有する、請求項16記載の組成物。
- 食品若しくは飲料、又は食品若しくは飲料のためのサプリメント組成物である、請求項1〜14のいずれか1項記載の組成物。
- EGCG、パンテチン又はその代謝産物、フィタン酸、リポ酸、ポリコサノール及びコエンザイムQ−10から選択される少なくとも2種の成分を含む食品又は飲料。
- 栄養補助組成物の製造における、EGCG、パンテチン又はその代謝産物、フィタン酸、リポ酸、ポリコサノール及びコエンザイムQ−10から選択される少なくとも2種の成分の使用。
- EGCGとパンテチンとの組合せ、又はEGCGとフィタン酸との組合せ、又はパンテチンとフィタン酸との組合せの、請求項22記載の使用であって、前記EGCGが、投与対象患者の体重1kg当たり日用量0.3mg〜約30mgを提供するのに十分な量で使用され、前記パンテチンが、投与対象患者の体重1kg当たり日用量1.0mg〜約50mgを提供するのに十分な量で使用され、そしてフィタン酸が、投与対象患者の体重1kg当たり日用量1.0mg〜約100mgを提供するのに十分な量で使用される組合せの使用。
- 栄養補助組成物が、食品若しくは飲料、又は食品若しくは飲料のためのサプリメント組成物である、請求項23記載の使用。
- 栄養補助組成物が、1型及び2型両方の糖尿病の治療を意図し、そして前糖尿病の患者における2型糖尿病、又は耐糖能障害(IGT)若しくは肥満症の予防を意図している、請求項23記載の使用。
- 栄養補助組成物が、1型及び2型両方の糖尿病の治療のため、そして前糖尿病の患者における2型糖尿病、又は耐糖能障害(IGT)若しくは肥満症の予防のための医薬組成物である、請求項23記載の使用。
- 1型及び2型両方の糖尿病の治療のための、そして前糖尿病の患者における2型糖尿病、又は耐糖能障害(IGT)若しくは肥満症の予防のための方法であって、そのような治療の必要な患者に、EGCG、パンテチン又はその代謝産物、フィタン酸、リポ酸、ポリコサノール及びコエンザイムQ−10から選択される少なくとも2種の成分を投与することを含む方法。
Applications Claiming Priority (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
EP02024804 | 2002-11-07 | ||
PCT/EP2003/010838 WO2004041257A2 (en) | 2002-11-07 | 2003-09-30 | Novel nutraceutical compositions comprising epigallocatechin gallate |
Publications (1)
Publication Number | Publication Date |
---|---|
JP2006508096A true JP2006508096A (ja) | 2006-03-09 |
Family
ID=32309314
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
JP2004548728A Pending JP2006508096A (ja) | 2002-11-07 | 2003-09-30 | 没食子酸エピガロカテキンを含む新規な栄養補助組成物 |
Country Status (6)
Country | Link |
---|---|
US (1) | US20060165671A1 (ja) |
EP (1) | EP1558244A2 (ja) |
JP (1) | JP2006508096A (ja) |
CN (1) | CN1694695A (ja) |
AU (1) | AU2003293592A1 (ja) |
WO (1) | WO2004041257A2 (ja) |
Cited By (8)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
JP2007269786A (ja) * | 2006-03-09 | 2007-10-18 | Daiichi Sankyo Healthcare Co Ltd | パンテチン含有経口液剤 |
JP2007297373A (ja) * | 2006-04-06 | 2007-11-15 | Taisho Pharmaceut Co Ltd | ユビデカレノン含有内服用組成物 |
JP2008031136A (ja) * | 2006-07-27 | 2008-02-14 | Bhn Kk | ヒアルロン酸産生増強剤 |
WO2009093737A1 (ja) * | 2008-01-25 | 2009-07-30 | Kobayashi Pharmaceutical Co., Ltd. | 抗肥満用医薬組成物 |
JP2010513250A (ja) * | 2006-12-15 | 2010-04-30 | ティーマ ファウンデーション | 組成物およびその使用 |
JPWO2008143182A1 (ja) * | 2007-05-17 | 2010-08-05 | 株式会社カネカ | 甘草ポリフェノールを含有する組成物 |
JP2010195827A (ja) * | 2010-05-12 | 2010-09-09 | Bhn Kk | 経口用老化防止剤及び美容方法 |
US9603847B2 (en) | 2006-12-15 | 2017-03-28 | Tima Foundation | Compositions and uses thereof |
Families Citing this family (14)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
WO2005006890A2 (en) * | 2003-07-10 | 2005-01-27 | Forest Carl A | Foods, beverages, condiments, spices and salad dressings with specialized supplements |
KR20060121887A (ko) | 2003-09-23 | 2006-11-29 | 디에스엠 아이피 어셋츠 비.브이. | 진성 당뇨병의 치료 및 예방용 조성물 |
CN101897970A (zh) * | 2003-12-19 | 2010-12-01 | 奥加生物药业(I.P.3)有限公司 | 用于治疗糖尿病的组合物和方法 |
MY142815A (en) | 2004-02-19 | 2011-01-14 | Univ Florida | Use of molt-accelerating compounds, ecdysteroids, analogs thereof, and chitin synthesis inhibitors for controlling termites. |
ITRM20040395A1 (it) * | 2004-08-03 | 2004-11-03 | Sigma Tau Ind Farmaceuti | Composizione comprendente statine e acidi grassi omega 3. |
JP4849792B2 (ja) * | 2004-09-14 | 2012-01-11 | オリザ油化株式会社 | 美容用組成物 |
JP5085329B2 (ja) * | 2005-09-12 | 2012-11-28 | 協和発酵バイオ株式会社 | α−リポ酸含有組成物 |
EA200802090A1 (ru) * | 2006-03-31 | 2010-04-30 | ДСМ АйПи АССЕТС Б.В. | Новое применение соединений и комбинаций соединений для улучшения внешнего вида |
WO2007118338A1 (en) * | 2006-04-19 | 2007-10-25 | Emmi Ag | Milk serum supplemented aqueous solutions |
US20100240581A1 (en) * | 2006-11-13 | 2010-09-23 | The Trustees Of Columbia University In The City Of New York | Selective proteasome inhibitors for treating diabetes |
ITMI20072051A1 (it) | 2007-10-23 | 2009-04-24 | Chimico Internaz S P A In Brev | Composizione a base di pellet di acido lipoico |
ITPI20110038A1 (it) * | 2011-04-08 | 2012-10-09 | Funcional Food Res S R L | Composizione alimentare funzionale a base di farina. |
US9226950B2 (en) * | 2013-11-12 | 2016-01-05 | National Dong Hwa University | Method and composition for treating diabetes mellitus |
TWI657815B (zh) * | 2013-11-12 | 2019-05-01 | 國立東華大學 | 用於治療糖尿病的方法與組合物 |
Citations (6)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
JPH03133928A (ja) * | 1989-10-19 | 1991-06-07 | Mitsui Norin Kk | α―アミラーゼ活性阻害剤 |
JPH04253918A (ja) * | 1991-02-05 | 1992-09-09 | Mitsui Norin Kk | 血糖上昇抑制剤 |
JPH0517352A (ja) * | 1991-07-03 | 1993-01-26 | Mitsui Norin Kk | シユクラーゼ活性阻害剤 |
JPH0517364A (ja) * | 1991-07-08 | 1993-01-26 | Mitsui Norin Kk | シユクラーゼ活性阻害剤 |
JPH11507385A (ja) * | 1995-06-07 | 1999-06-29 | エルゴ サイエンス インコーポレイティド | グルコース代謝の調節法 |
JP2002104964A (ja) * | 2000-08-04 | 2002-04-10 | Roche Vitamins Ag | 糖尿病処置のためのフィタン酸の使用 |
Family Cites Families (12)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US5318986A (en) * | 1989-10-19 | 1994-06-07 | Mitsui Norin Co., Ltd. | Method of inhibiting the activity of α-amylase |
US5599835A (en) * | 1994-11-23 | 1997-02-04 | Fischer; Frederick B. | Use of DL-lipoic acid as a medical food in the treatment of diabetes mellitus |
US5976568A (en) * | 1997-02-21 | 1999-11-02 | Medical Doctors' Research Institute, Inc. | Modular system of dietary supplement compositions for optimizing health benefits and methods |
US5922756A (en) * | 1998-02-14 | 1999-07-13 | Chan; Marion Man-Ying | Method of inhibiting nitric oxide synthase |
US6335361B1 (en) * | 1999-11-03 | 2002-01-01 | Juvenon Inc. | Method of treating benign forgetfulness |
US20020155163A1 (en) * | 1999-12-27 | 2002-10-24 | Samuel D. Benjamin | Integrated multi-vitamin and mineral combination |
EP1177789A3 (en) * | 2000-08-04 | 2003-01-29 | Roche Vitamins AG | Use of phytanic acid for the treatment of diabetes |
US6579866B2 (en) * | 2000-12-28 | 2003-06-17 | Mccleary Larry | Composition and method for modulating nutrient partitioning |
ITVR20010031A1 (it) * | 2001-03-12 | 2002-09-12 | Hisanori Suzuki | Uso di epigallocatechin-3-gallato o suoi derivati nella profilassi e nel trattamento delle malattie neurodegenerative. |
NL1017707C2 (nl) * | 2001-03-27 | 2002-10-01 | Jaap Meijer | Vitaminepreparaat. |
US6565896B1 (en) * | 2002-07-03 | 2003-05-20 | Vitacost.Com, Inc. | Cholesterol treatment formulation |
AU2003266287A1 (en) * | 2002-08-23 | 2004-03-11 | Dsm Ip Assets B.V. | Novel nutraceutical compositions comprising biotin |
-
2003
- 2003-09-30 CN CNA038246627A patent/CN1694695A/zh active Pending
- 2003-09-30 JP JP2004548728A patent/JP2006508096A/ja active Pending
- 2003-09-30 EP EP03788928A patent/EP1558244A2/en not_active Withdrawn
- 2003-09-30 WO PCT/EP2003/010838 patent/WO2004041257A2/en active Application Filing
- 2003-09-30 AU AU2003293592A patent/AU2003293592A1/en not_active Abandoned
- 2003-09-30 US US10/533,858 patent/US20060165671A1/en not_active Abandoned
Patent Citations (6)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
JPH03133928A (ja) * | 1989-10-19 | 1991-06-07 | Mitsui Norin Kk | α―アミラーゼ活性阻害剤 |
JPH04253918A (ja) * | 1991-02-05 | 1992-09-09 | Mitsui Norin Kk | 血糖上昇抑制剤 |
JPH0517352A (ja) * | 1991-07-03 | 1993-01-26 | Mitsui Norin Kk | シユクラーゼ活性阻害剤 |
JPH0517364A (ja) * | 1991-07-08 | 1993-01-26 | Mitsui Norin Kk | シユクラーゼ活性阻害剤 |
JPH11507385A (ja) * | 1995-06-07 | 1999-06-29 | エルゴ サイエンス インコーポレイティド | グルコース代謝の調節法 |
JP2002104964A (ja) * | 2000-08-04 | 2002-04-10 | Roche Vitamins Ag | 糖尿病処置のためのフィタン酸の使用 |
Non-Patent Citations (3)
Title |
---|
JPN5005010792, RETT K, DIABETES AND STOFFOWECHSEL, 1996, V5 N. SUPPL. 3, P59−63, DE * |
JPN5005010793, MCCARTY M F, MEDICAL HYPOTHESES, 200005, V54 N5, P786−793, US, EDEN PRESS * |
JPN5005010794, MCCARTY M F, MEDICAL HYPOTHESES, 2001, V57 N3, P324−336, GB * |
Cited By (10)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
JP2007269786A (ja) * | 2006-03-09 | 2007-10-18 | Daiichi Sankyo Healthcare Co Ltd | パンテチン含有経口液剤 |
JP2007297373A (ja) * | 2006-04-06 | 2007-11-15 | Taisho Pharmaceut Co Ltd | ユビデカレノン含有内服用組成物 |
JP2008031136A (ja) * | 2006-07-27 | 2008-02-14 | Bhn Kk | ヒアルロン酸産生増強剤 |
JP4556061B2 (ja) * | 2006-07-27 | 2010-10-06 | ビーエイチエヌ株式会社 | ヒアルロン酸産生増強剤 |
JP2010513250A (ja) * | 2006-12-15 | 2010-04-30 | ティーマ ファウンデーション | 組成物およびその使用 |
JP2014132017A (ja) * | 2006-12-15 | 2014-07-17 | Tima Foundation | 組成物およびその使用 |
US9603847B2 (en) | 2006-12-15 | 2017-03-28 | Tima Foundation | Compositions and uses thereof |
JPWO2008143182A1 (ja) * | 2007-05-17 | 2010-08-05 | 株式会社カネカ | 甘草ポリフェノールを含有する組成物 |
WO2009093737A1 (ja) * | 2008-01-25 | 2009-07-30 | Kobayashi Pharmaceutical Co., Ltd. | 抗肥満用医薬組成物 |
JP2010195827A (ja) * | 2010-05-12 | 2010-09-09 | Bhn Kk | 経口用老化防止剤及び美容方法 |
Also Published As
Publication number | Publication date |
---|---|
EP1558244A2 (en) | 2005-08-03 |
AU2003293592A8 (en) | 2004-06-07 |
AU2003293592A1 (en) | 2004-06-07 |
CN1694695A (zh) | 2005-11-09 |
WO2004041257A3 (en) | 2004-08-05 |
US20060165671A1 (en) | 2006-07-27 |
WO2004041257A2 (en) | 2004-05-21 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
US11219590B2 (en) | Anti-aging agent and anti-aging method | |
JP2006508096A (ja) | 没食子酸エピガロカテキンを含む新規な栄養補助組成物 | |
JP5566946B2 (ja) | 新規栄養補助食品組成物及びその使用 | |
US20050256178A1 (en) | Novel nutraceutical compositions comprising boitin | |
US8129337B2 (en) | Compositions comprising epigallocatechin gallate and protein hydrolysate | |
US20220031596A1 (en) | Anti-aging agent and anti-aging method | |
WO2004105739A1 (ja) | 高級脂肪酸誘導体含有組成物及び飲食物 | |
US7691420B2 (en) | Compositions for the treatment and prevention of diabetes mellitus | |
US20090221694A1 (en) | Nutraceutical compositions comprising epigallocatechin gallate and raspberry ketone | |
KR20170027272A (ko) | D-싸이코스를 유효성분으로 함유하는 지질 관련 대사성 질환의 예방 또는 치료용 조성물 | |
US20200068939A1 (en) | Nutritional compositions to increase and sustain blood ketone levels | |
JP2006022064A (ja) | 動脈硬化の予防及び/又は改善剤、機能性食品、又は化粧料 | |
AU2003292049B2 (en) | Nutraceutical compositions comprising epigallocatechin gallate and raspberry ketone | |
EP3622951B1 (en) | Agent for raising total ketone concentration, oil and fat composition, pharmaceutical composition, and food product composition | |
KR101719015B1 (ko) | 프루네틴을 유효성분으로 함유하는 비만 또는 대사성 질환의 예방 또는 치료용 약학적 조성물 | |
JP2006137730A (ja) | 抗疲労作用剤又は持久力増強剤、機能性食品又は化粧料 |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
A621 | Written request for application examination |
Free format text: JAPANESE INTERMEDIATE CODE: A621 Effective date: 20060929 |
|
RD03 | Notification of appointment of power of attorney |
Free format text: JAPANESE INTERMEDIATE CODE: A7423 Effective date: 20061130 |
|
RD04 | Notification of resignation of power of attorney |
Free format text: JAPANESE INTERMEDIATE CODE: A7424 Effective date: 20061204 |
|
A131 | Notification of reasons for refusal |
Free format text: JAPANESE INTERMEDIATE CODE: A131 Effective date: 20100126 |
|
A02 | Decision of refusal |
Free format text: JAPANESE INTERMEDIATE CODE: A02 Effective date: 20100629 |